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The importance of xanthone derivatives is considerable. They possess large variety 
of biological and pharmacological activities. Many of them proved to be important 
building blocks for synthesis of new compounds.  
Chirality is a fundamental property of biological systems and reflects the underlying 
asymmetry of matter. Almost one-third of all drug sales worldwide are chiral 
compounds and the authorities recommend that the chiral drugs should be saled in pure 
enantiomeric forms because enantiomers may differ both quantitatively and 
qualitatively in their biological activities. At one extreme, one enantiomer may be 
devoid of any biological activity; at the other extreme, both enantiomers may have 
qualitatively different biological activities. Enantiomers also differ in bioavailability – 
one enantiomer can be more bioavailable than the other, also the volume of distribution 
is different for levo and dextro enantiomer. 
 
The synthesis of the xanthone derivative (XD) 2-carboxy-6-methoxyxanthone was a 
six-step reaction:  
1. Synthesis of dimethyl 4-bromoisophthalate by Fisher esterification. 
2. N,N-Dimethylglycine-promoted Ullmann condensation of dimethyl 4-bromoiso-
phthalate with 3-methoxyphenol to get dimethyl 4-(3'-methoxyphenoxy) 
isophthalate.  
3. Hydrolysis of dimethyl 4-(3'-methoxyphenoxy)isophthalate to obtain 
4-(3'-methoxyphenoxy)isophthalic acid. 
4. Synthesis of 2-carboxy-6-methoxyxanthone and 2-carboxy-8-methoxyxanthone by 
an intramolecular acylation. 
5. Esterification of 2-carboxy-6-methoxyxanthone and 2-carboxy-8-methoxy-
xanthone. 
6. Hydrolysis of methyl 6-methoxyxanthone-2-carboxylate to obtain 2-carboxy-
6-methoxyxanthone. 
 
2-Carboxy-6-methoxyxanthone was used as a building block for synthesis of an 
enantiomerically pure compound, namely N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-
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6-methoxyxanthone-2-carboxamide by a coupling reaction with the amino alcohol 
D-valinol. 





C Nuclear Magnetic Resonance (NMR) and by 









Důležitost derivátů xanthonu je nesporná. Mají širokou škálu biologických 
a farmakologických účinků. Mnoho z nich se stalo důležitými stavební bloky pro 
syntézu nových sloučenin.  
Chiralita je základní vlastností biologických systémů a odráží základní asymetrie 
hmoty. Téměř jedna třetina prodeje všech léků po celém světě jsou chirální sloučeniny 
a autority doporučují, aby chirální léky byly prodávány pouze v čistých enantiomerních 
formách. Důvodem je, že se enantiomery mohou lišit kvantitativně i kvalitativně 
v jejich biologické aktivitě. V prvním extrému, může jeden enantiomer postrádat 
biologickou aktivitu, v opačném extrému, mohou mít oba enantiomery kvalitativně 
odlišné biologické aktivity.  Enantiomery se také liší v biologické dostupnosti – jeden 
enantiomer může být více biologicky dostupný než ostatní, i distribuční objem je jiný 
pro levo a jiný pro dextro enantiomer. 
 
Syntéza derivátu xanthonu (XD) 2-karboxy-6-methoxyxanthonu zahrnovala šest 
reakčních kroků: 
1. Syntéza dimethyl-4-bromoisoftalátu Fisherovou esterifikací. 
2. Ullmannova kondenzace dimethyl-4-bromisoftalátu s 3-methoxyfenolem 
podporovaná N,N-dimethylglycinem za vzniku dimethyl-4-(3'-methoxyphenoxy) 
isoftalátu.  
3. Hydrolýza dimethyl 4-(3'-methoxyphenoxy)isoftalátu. 
4. Syntéza 2-karboxy-6-methoxyxanthonu a 2-karboxy-8-methoxyxanthonu 
intramolekulární acylací. 
5. Esterifikace 2-karboxy-6-methoxyxanthonu a 2-karboxy-8-methoxyxanthonu. 
6. Hydrolýza methyl-6-methoxyxanthon-2-karboxylátu za vzniku 2-karboxy-
6-methoxyxanthonu. 
 
2-karboxy-6-methoxyxanthon byl použit jako stavební blok pro syntézu 
enantiomerně čisté sloučeniny, jmenovitě N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-
6-methoxyxanthon-2-karboxamidu, který byl syntetizován spojením 




Skoro všechny připravené sloučeniny byly strukturně charakterizované různými 
spektroskopickými metodami: 
1
H NMR and 
13
C NMR (nukleární magnetickou 










Abbrevitations and symbols 
 
13
C NMR = carbon nuclear magnetic resonance  
1
H NMR = proton nuclear magnetic resonance  
AMP = adenosine monophosphate  
CEQUIMED-UP = Centro de Química Medicinal da Universidade do Porto 
CDCl3 = deuterated chloroform 
CNS = central nervous system  
δ = chemical shift   
d = doublet 
dd = double doublet  
DMSO-d6 = dimethyl-d6 sulfoxide 
Hz = hertz 
IR = infrared spectroscopy  
J = coupling constant 
M = multiplet 
MAO = monoamine oxidase   
MeOH= methanol  
MHz = megahertz 
MP = melting point  
ppm = parts per million 
QSAR = quantitative structure-activity relationship  
s = singlet 
SAR = structure-activity relationship  
t = triplet  
TBTU = O-(benzotriazol-1-yl)-N, N, N’, N’-tetramethylluronium tetrafluoroborate 
THF = tetrahydrofuran   
TLC = thin layer chromatography  
TNF = tumor necrosis factor 
UV = ultraviolet  
νmax = maximal frequency 





1.1. Xanthones generally 
 
The xanthones or 9H-xanthen-9-ones (Fig. 1) comprise an important class of 
oxygenated heterocycles. The term xanthone (from the Greek ó (xanthos), 
meaning yellow, designates heterocyclic compounds having a dibenzo-γ-pyrone 
skeleton as basic structure.  Natural xanthones can be subdivided, depending on the 
nature of the substituents in the dibenzo-γ-pyrone scaffold, into six main groups: simple 
oxygenated xanthones (mono, di, tri, tetra, penta and hexaoxygenated), glycosylated 
xanthones, prenylated xanthones and their derivatives, xanthonolignoids, bis-xanthones 
and miscellaneous. On the other hand, xanthones of synthetic origin can have simple 
groups such as hydroxyl, methoxyl, methyl, carboxyl, as well as more complex 
substituents such as epoxide, azole, methylidenebutyrolactone, aminoalcohol, 
sulfamoyl, methylthiocarboxylic, and dihydropyridine in their scaffold. [1-4] 
 
 
Fig. 1 Xanthone nucleus and numbering 
 
A number of xanthone derivatives are secondary plant metabolites and have been 
isolated from several natural sources like lichens, fungi, microorganisms and a few 
higher plants, mainly belonging to Anacardiaceae (Mangifera), Guttiferae (Garcinia, 
Platonia) and Gentianaceae (Gentiana, Swertia) families. All these oxygenated 
heterocyclic derivatives possess a structural relationship to other γ-pyrone natural 
products, namely flavonoids and chromones and have attracted, over the years, 






1.2. Xanthones and their biological activity 
 
Pharmacological investigations of xanthones date back to 1968, when 
Bhattacharya’s group reported the diuretic and cardiotonic actions of the natural 
glycoside mangiferin. [8] Since that many other biological activities for xanthone 
derivatives has been described, and several pharmacological studies were carried out. 
[5,6,9] Some structure-activity relationship (SAR) studies have recently been described 
for the following activities: tuberculostatic, antimycotic, antimalarial, antiplatelet, 
antithrombotic, anti-inflammatory, anticonvulsant, antiallergic, antitumor, 
antimutagenic, and antioxidant. Furthermore, SAR studies have been also developed in 
the field of adrenergic blocking agents, calcium antagonists, P-glycoprotein modulators, 
leukotriene LTB4 receptors blocking agents, as well as for effects on several enzymes, 
such as acetylcholinesterase, aldose reductase, aromatase, cAMP phosphodiesterase, 
human cytochrome P450 17-α-hydroxylase-17,20-lyase, monoamine oxidase (MAO), 
sphingomyelinases, and protein kinases. [1]  
From the available SARs, quantitative structure-activity relationship (QSAR) 
studies are emerging for tuberculostatic agents and MAO inhibitors. More recently, 
computational studies have been developed in the field of antimalarial agents using 
docking studies to obtain a correlation between xanthone derivatives and 
hematin/hemazoin targets. [1,7] 
As phenolic compounds, xanthones have been reported for their antioxidant 
properties. They can act as metal chelators, free radical scavengers, as well as inhibitors 
of lipid peroxidation. These properties have been implicated in their hepatoprotective, 
anti-inflammatory and cancer chemopreventive actions. [1,7] 
The in vitro inhibitory activity of xanthones on tumor cell lines is remarkable. They 
can act on wide range of tumor cell lines, like leukemia, multiple myeloma, oral 
squamous cell carcinoma, melanoma, colon carcinoma, breast adenocarcinoma, ovarian 
carcinoma, uterine carcinoma, prostate carcinoma, lung carcinoma, liver carcinoma, 
stomach carcinoma, renal carcinoma, pancreatic carcinoma, central nervous system 
(CNS) carcinoma, glioma, colorectal carcinoma, hepatoma, bladder carcinoma, 
neuroblastoma, pheochromocytoma, adrenocortical carcinoma, fibroblasts tumor cells, 
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fibrosarcoma, epithelial tumor cells, nasopharynx epidermoid carcinoma and further 
more. Also in vivo studies have been carried out for example in colon adenocarcinoma, 
lymphocytic leukemia, ovarian carcinoma, melanoma, pancreatic carcinoma, sarcoma, 
glioma and further more. [1] 
 
1.2.1. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) 
 
DMXAA (Fig. 2) is an anticancer drug with an unusual mechanism of action 
compared with conventional cytotoxic anticancer drugs. DMXAA induces rapid 
vascular collapse and necrosis in transplantable murine tumours, thought to be due to 
immune modulation and the induction of cytokines, in particular TNF-, interferons, 
serotonin and nitric oxide. Co-administration of DMXAA with other drugs has been 
shown to result in enhanced antitumour activity and alterations in pharmacokinetics, as 
reported for the combination of DMXAA with melphalan, thalidomide, and the 
bioreductive agent tirapazamine, in mouse models. DMXAA is metabolized by 
glucuronidation that is catalyzed by uridine diphosphate glucuronosyltransferases and 




Fig. 2 DMXAA 
 
1.2.2. Psorospermin  
 
Psorospermin (Fig. 3) is a natural dihydrofuranoxanthone, isolated from the roots 
and bark of a tropical African plant Psorospermum febrifugum (Guttiferae),  in 
advanced preclinical development. This natural product was shown to have both in vitro 
and in vivo (in mice models) antileukaemic activity and to be active against several 
13 
 
human tumor cell lines from different tumor types such as breast, colon, lymphocytic 
leukemia, drug-resistant leukemias, and in AIDS-related lymphoma. Psorospermin acts 
by the intercalation into the DNA molecule and by the guanin alkylation at the 
topoisomerase II cleavage site. [1,6,14] 
 
 




Mangiferin, 1,3,6,7-tetrahydroxyxanthone-2-C-ß-D-glucopyranosyl (Fig. 4), is a 
widely distributed polyphenol in higher plants (Mangifera indica, Salacia reticulata, 
Cratoxylum cochinchinensis, Polygala elongata) and is well-known for its antioxidant, 
anti-inflammatory, immunomodulatory, antidiabetic, antitumor, antibacterial, anti-HIV 
and antiviral effects. Interestingly, mangiferin was the first xanthone to be investigated 
for pharmacological purposes. In Cuba, mangiferin is traditionally used as an anti-
inflammatory, analgesic and also as an antioxidant under brand name Vimang. In Sri 
Lanka, mangiferin has been used in the obesity treatment and particularly for diabetes 





Fig. 4 Mangiferin 
1.2.4. Mangosteen 
 
Garcinia mangostana L. (Clusiaceae) is commonly known as mangosteen and 
“mangkhut”, and its fruits (Fig. 5) are referred to, in Thailand, as the “queen of fruits”, 
as a result of its delicious taste. The mangosteen plant grows slowly to 7 – 12 m high. 
The pericarps of mangosteen have been used for many years in traditional medicine for 
the treatment of skin infection, diarrhea, dysentery, inflammation, cancer (leukemia, 
hepatocellular carcinoma, gastric, breast and lung tumor), ulcers and wounds. The 
extract of Garcinia mangostana L. contains prenylated and glycosyl prenylated 












Chirality is a fundamental property of biological systems and reflects the underlying 
asymmetry of matter. The molecules that are not superimposable with its own image in 
the mirror and, then, exist in two enantiomeric forms, are considered chiral. These 
enantiomers are optical stereoisomers, because they possess optical activity. The 
simplest model for a chiral molecule is the carbon atom linked to four different groups. 
Such carbons are designated as stereogenic, assymetrical or chirality centers. 
Compounds that contain both mirror-image enantiomers in equal proportions are 
referred to as racemic mixtures or racemates. It is important to point out that 
enantiomers have the same physical and chemical properties, such as solubility or 
melting point. The two enantiomeric forms can be distingued by their optical activity, 
which consists in the property of rotating the plane of polarized light. 
The conventions that have been used to designate the enantiomers are R and 
S according to Cahn, Ingold and Prelog (more systematic, universaly used), and D and 
L, used in molecules of biochemic importace like sugars and amino acids. The symbols 
(+) or d for dextrorotatory and (-) or l for levorotatory designate optical rotation. [19-21] 
Many biological events involve proteins with asymmetry originated by the intrinsic 
chirality of the fundamental building blocks – the L-amino acids. In broad sense drug 
receptor interactions have long been known to be stereoselective. Enantiomers may 
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differ both quantitatively and qualitatively in their biological activities. At one extreme, 
one enantiomer may be devoid of any biological activity; at the other extreme, both 
enantiomers may have qualitatively different biological activities. These stereoselective 
differences may arise not only from drug interactions at pharmacological receptors, but 
also from pharmacokinetic events, including protein binding, metabolism and transport. 
[22] 
Active transport processes may discriminate between the enantiomers, with 
implications in bioavailability – one enantiomer can be more bioavailable than the 
other, also the volume of distribution is different for levo and dextro enantiomer. Drug 
metabolizing enzyme systems are also subject to stereoselective influences. Two 
isomers of a drug are often metabolized at different rates. This may result in 
accumulation of the inactive enantiomer or rapid elimination of the active one and vice 
versa. Two isomers of a drug also induce or inhibit the cytochrome enzymes 
stereoselectively. 
The potential advantages of using enantiomeric pure drugs are:  
 less complex, more selective pharmacodynamic profile 
 potential for an improved therapeutic index 
 less complex pharmacokinetic profile 
 reduced potential for complex drug interactions 
 less complex relationship between plasma concentration and effect. [24] 
A number of general reviews are available outlining stereoselectivity in both drug 
action and disposition and also giving some possible advantages of single enantiomers 
of a range of agents including antimalarial drugs, bronchodilators, β-blockers, 






2. OBJECTIVES AND PLANNING 
 
Xanthones are a group of compounds with very important biological activities. 
Many of them are important building blocks for further synthesis of new interesting 
compounds. The group in the Faculty of Pharmacy of UP (CEQUIMED-UP) has a vast 
experience in synthesis and structure elucidation of XDs. 
The aims of this work are  
 Synthesis of the xanthone derivative 2-carboxy-6-methoxyxanthone using a six-
step reaction. 
 Synthesis of the chiral xanthone derivative N-[(1R)-1-(hydroxymethyl)-
2-methylpropyl]-6-methoxyxanthone-2-carboxamide, by coupling 2-carboxy-
6-methoxyxanthone with the amino alcohol D-valinol. 







3. RESULTS AND DISCUSSION 
 
Results and discussion have been included into Attachment due to confidential 
reasons. 
 
4. EXPERIMENTAL PART 
 







A number of compounds were successfully synthesized in this work: 
 Dimethyl 4-bromoisophthalate (2): 10.98 g, 60% 
 Dimethyl 4-(3'-methoxyphenoxy)isophthalate (4): 0.28 g, 25% and 6.3273 g, 
54% 
 4-(3'-Methoxyphenoxy)isophthalic acid (5): 4.95 g, 83% 
 2-Carboxy-6-methoxyxanthone (6): 3.51 g, 94% 
 Methyl 6-methoxyxanthone-2-carboxylate (8): 4.02 g 
 N-[(1R)-1-(Hydroxymethyl)-2-methylpropyl]-6-methoxyxanthone-
2-carboxamide (10): 0.72 g, 75%. 
 
The structures of the compounds 2, 4, 5, 6, 8, 10 were successfully elucidated using 






In 2011, similar compound have been patented as builging blocks for the 
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